GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed ...
Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its ...
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...
Hosted on MSN
ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered health ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
GARDEN CITY, NY, Feb. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has begun new saliva-based, viral RT-PCR multiplex-testing ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results